DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...
On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...
Smartwatches may transform blood sugar tracking, but today’s advances depend on CGMs, AI, and regulated health tech ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless ...
AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
Morning Overview on MSN
The FDA cleared the first over-the-counter glucose monitor made for children
Parents of young children with elevated blood sugar now have a new option that does not require a doctor’s prescription. The Food and Drug Administration cleared Dexcom’s Stelo Glucose Biosensor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results